X0206 3 2019-05-07 0 0001563880 Trevi Therapeutics, Inc. TRVI 0001385155 Meeker David P C/O TREVI THERAPEUTICS, INC. 195 CHURCH STREET, 14TH FLOOR NEW HAVEN CT 06510 1 0 1 0 Series A Preferred Stock Common Stock 128211 D Series A Preferred Stock Common Stock 27426 I By Trevi 2014 Irrevocable Trust Series A Preferred Stock Common Stock 13268 I By Spinnaker Trust as Trustee for Trevi 2014 Irrevocable Trust Series B Preferred Stock Common Stock 116345 D Series C Preferred Stock Common Stock 55902 D Stock Option (right to buy) 3.14 2023-03-10 Common Stock 4211 D Stock Option (right to buy) 3.23 2024-01-22 Common Stock 3878 D Stock Option (right to buy) 2.19 2024-07-01 Common Stock 5925 D Stock Option (right to buy) 1.43 2024-11-24 Common Stock 4555 D Stock Option (right to buy) 3.33 2027-12-19 Common Stock 26316 D The Series A Preferred Stock and the dividends that have accrued thereon to date are convertible on a 9.5-for-one basis into the number of shares of Common Stock shown in Column 3 without payment of further consideration at the holder's election or automatically upon the closing of the Issuer's initial public offering. The number of shares of Common Stock into which the Series A Preferred Stock and accrued dividends thereon are convertible will increase on a daily basis without payment of further consideration as additional dividends accrue. The shares have no expiration date. The Series B Preferred Stock and the dividends that have accrued thereon to date are convertible on a 9.5-for-one basis into the number of shares of Common Stock shown in Column 3 without payment of further consideration at the holder's election or automatically upon the closing of the Issuer's initial public offering. The number of shares of Common Stock into which the Series B Preferred Stock and accrued dividends thereon are convertible will increase on a daily basis without payment of further consideration as additional dividends accrue. The shares have no expiration date. The Series C Preferred Stock and the dividends that have accrued thereon to date are convertible on a 9.5-for-one basis into the number of shares of Common Stock shown in Column 3 without payment of further consideration at the holder's election or automatically upon the closing of the Issuer's initial public offering. The number of shares of Common Stock into which the Series C Preferred Stock and accrued dividends thereon are convertible will increase on a daily basis without payment of further consideration as additional dividends accrue. The shares have no expiration date. This option was granted on March 11, 2013. The 4,211 shares of common stock underlying the option vested over four years from the date of grant in equal monthly installments. This option was granted on January 23, 2014. The 3,878 shares of common stock underlying the option vested over four years from the date of grant in equal monthly installments. This option was granted on July 2, 2014. The 5,925 shares of common stock underlying the option vested over four years from June 11, 2014 in equal monthly installments. This option was granted on November 25, 2014. The 4,555 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and as to the remaining 75% of the shares in equal quarterly installments thereafter through November 25, 2018. This option was granted on December 20, 2017. The 26,316 shares of common stock underlying the option are scheduled to vest over four years from the date of grant in equal quarterly installments. Exhibit Index: 24.1 Power of Attorney /s/ David P. Meeker 2019-05-07